We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Biovendor Group presents its CLIA, NGS, Microblot Array, microRNA and LAMP Product Lines at MEDICA 2021

By HospiMedica International staff writers
Posted on 15 Nov 2021
Image: KleeYa fully automated analyzer (Photo courtesy of BioVendor)
Image: KleeYa fully automated analyzer (Photo courtesy of BioVendor)
BioVendor Group (Brno, Czech Republic) presented its CLIA, NGS, Microblot Array, microRNA and LAMP product lines at the 2021 edition of MEDICA, the world's largest trade fair for medical technology, held from 15 to 18 November in Düsseldorf, Germany.

BioVendor presented its newly-launched KleeYab fully automated analyzer, a highly flexible, fast and sensitive random access chemiluminescence platform that provides a unique approach to the use of different bead-based chemiluminescence technologies, offering superior assay performance and providing ease of use with cost containment. The open platform system features a unique trigger cartridge technology that allows the use of both flash and glow detection technologies, along with unique stackable reaction cuvettes to eliminate system handling errors and reduce shipping and storage space.

BioVendor demonstrated its new Next Generation Sequencing (NGS) technology, fastGEN designed for examination of the mutation status of oncomarkers in samples. Its technology is based on ultra-deep sequencing of short amplicons obtained by a single polymerase chain reaction with special tagged hybrid primers. The fastGEN technology is simple, ultra-sensitive, specific and effective - it is perfectly adapted to diagnostics and offers new advantages for clinical material.

At MEDICA 2021, BioVendor also demonstrated its Microblot-Array (MBA), a new generation of a market-unique immunoblot array in a microtiter plate format. It is designed for efficient multiplex diagnostics, enabling the simultaneous detection of multiple markers which is time and cost-saving. The technology eliminates the limited capacity of traditional BLOT strips and opens the way to high throughput testing. Simple processing can be done manually or automatically using any open ELISA analyzers. Additionally, BioVendor presented its complete solution for microRNAs (miRNAs) and other short non-coding RNA sequences (sncRNA) projects, starting with isolation, followed by screening for proper targets and their final quantification. BioVendor also showcased its loop-mediated isothermal amplification (LAMP) assays which bring a novel approach for direct detection of target nucleic acids without the need of isolation step. The unique architecture of the LAMP method ensures its high sensitivity and specificity, and a tolerance for inhibitory substances.

Related Links:
BioVendor Group

Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Endoscopy Display
E190
Absorbable Monofilament Mesh
Phasix Mesh

Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more